Εμφάνιση απλής εγγραφής

dc.creatorGiannakou S., Angelidis G., Tsougos I., Valotassiou V., Kappas K., Georgoulias P.en
dc.date.accessioned2023-01-31T07:41:52Z
dc.date.available2023-01-31T07:41:52Z
dc.date.issued2020
dc.identifier10.1007/s12149-020-01458-7
dc.identifier.issn09147187
dc.identifier.urihttp://hdl.handle.net/11615/72317
dc.description.abstractMost of the acute ischemic events, such as acute coronary syndromes and stroke, are attributed to vulnerable plaques. These lesions have common histological and pathophysiological features, including inflammatory cell infiltration, neo-angiogenesis, remodelling, haemorrhage predisposition, thin fibrous cap, large lipid core, and micro-calcifications. Early detection of the presence of a plaque prone to rupture could be life-saving for the patient; however, vulnerable plaques usually cause non-haemodynamically significant stenosis, and anatomical imaging techniques often underestimate, or may not even detect, these lesions. Although ultrasound techniques are currently considered as the “first-line” examinations for the diagnostic investigation and treatment monitoring in patients with atherosclerotic plaques, positron emission tomography (PET) imaging could open new horizons in the assessment of atherosclerosis, given its ability to visualize metabolic processes and provide molecular-functional evidence regarding vulnerable plaques. Moreover, modern hybrid imaging techniques, combining PET with computed tomography or magnetic resonance imaging, can evaluate simultaneously both functional and morphological parameters of the atherosclerotic plaques, and are expected to significantly expand their clinical role in the future. This review summarizes current research on the PET imaging of the vulnerable atherosclerotic plaques, outlining current and potential applications in the clinical setting. © 2020, The Japanese Society of Nuclear Medicine.en
dc.language.isoenen
dc.sourceAnnals of Nuclear Medicineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85082083645&doi=10.1007%2fs12149-020-01458-7&partnerID=40&md5=a801f57ee0ff32abcf9263c19f91d1ef
dc.subject1 fluoro 3 (2 nitro 1 imidazolyl) 2 propanol f 18en
dc.subjectarginine glycine aspartate f 18en
dc.subjectdotanoc ga 68en
dc.subjectfluciclatide f 18en
dc.subjectfluorocholine f 18en
dc.subjectfluorodeoxyglucose f 18en
dc.subjectgallium dotatate ga 68en
dc.subjectglycoprotein IIb IIIa platelet receptor f 18en
dc.subjecthx4 f 18en
dc.subjectlipocortin 5 f 18en
dc.subjectn sec butyl 1 (2 chlorophenyl) n methyl 3 isoquinolinecarboxamide c 11en
dc.subjectsodium fluoride f 18en
dc.subjecttetraxetan cu 64en
dc.subjecttraceren
dc.subjectunclassified drugen
dc.subjectangiogenesisen
dc.subjectapoptosisen
dc.subjectatherosclerosisen
dc.subjectatherosclerotic plaqueen
dc.subjecthumanen
dc.subjecthypoxiaen
dc.subjectmacrophageen
dc.subjectpathophysiologyen
dc.subjectpositron emission tomographyen
dc.subjectpriority journalen
dc.subjectReviewen
dc.subjectatherosclerotic plaqueen
dc.subjectdiagnostic imagingen
dc.subjectpositron emission tomographyen
dc.subjectproceduresen
dc.subjectHumansen
dc.subjectPlaque, Atheroscleroticen
dc.subjectPositron-Emission Tomographyen
dc.subjectRadioactive Tracersen
dc.subjectSpringeren
dc.titlePet tracers for vulnerable plaque imagingen
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής